{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:52:43Z","timestamp":1792641163943,"version":"4.5.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mastocytosis is a unique and rare neoplasm defined by abnormal expansion and accumulation of clonal mast cells (MCs) in one or multiple organ systems. Most adult patients are diagnosed to have systemic mastocytosis (SM). Based on histological findings and disease-related organ damage, SM is classified into indolent SM (ISM), smoldering SM (SSM), SM with an associated hematologic non-MC-lineage disease (SM-AHNMD), aggressive SM (ASM), and MC leukemia (MCL). The clinical picture, course, and prognosis vary profoundly among these patients. Nonetheless, independent of the category of SM, neoplastic cells usually exhibit the KIT point-mutation D816V. However, in advanced SM, additional molecular defects are often detected and are considered to contribute to disease progression and drug resistance. These lesions include, among others, somatic mutations in TET2, SRSF2, ASXL1, CBL, RUNX1, and RAS. In SM-AHNMD, such mutations are often found in the \u201cAHNMD component\u201d of the disease. Clinical symptoms in mastocytosis result from (1) the release of proinflammatory and vasoactive mediators from MCs, and (2) SM-induced organ damage. Therapy of SM has to be adjusted to the individual patient and the SM category: in those with ISM and SSM, the goal is to control mediator secretion and\/or mediator effects, to keep concomitant allergies under control, and to counteract osteoporosis, whereas in advanced SM (ASM, MCL, and SM-AHNMD) anti-neoplastic drugs are prescribed to suppress MC expansion and\/or to keep AHNMD cells under control. Novel drugs directed against mutated KIT and\/or other oncogenic kinase targets are tested currently in these patients. In rapidly progressing and drug-resistant cases, high-dose polychemotherapy and stem cell transplantation have to be considered.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.98","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T11:23:25Z","timestamp":1473938605000},"page":"98-105","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":39,"title":["Diagnosis and management of mastocytosis: an emerging challenge in applied hematology"],"prefix":"10.1182","volume":"2015","author":[{"given":"Peter","family":"Valent","sequence":"first","affiliation":[{"name":"Department of Medicine I, Division of Hematology and Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111709230767900_B1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2004.02.045","article-title":"Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms","volume":"114","author":"Valent","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"2019111709230767900_B2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"2019111709230767900_B3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/ehm.10.42","article-title":"Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives","volume":"3","author":"Arock","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"2019111709230767900_B4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal. Report of \u201cYear 2000 Working Conference on Mastocytosis.\u201d","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"2019111709230767900_B5","first-page":"291","article-title":"Mastocytosis","author":"Valent","year":"2001"},{"key":"2019111709230767900_B6","first-page":"54","article-title":"Mastocytosis (mast cell disease)","volume-title":"Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues","author":"Horny","year":"2008"},{"key":"2019111709230767900_B7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"key":"2019111709230767900_B8","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"2019111709230767900_B9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/blood-2009-10-249979","article-title":"WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults","volume":"115","author":"Pardanani","year":"2010","journal-title":"Blood"},{"key":"2019111709230767900_B10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"2019111709230767900_B11","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"2019111709230767900_B12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"2019111709230767900_B13","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"2019111709230767900_B14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"2019111709230767900_B15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/all.12126","article-title":"Definition and classification of mast cell activation syndromes","volume":"68","author":"Valent","year":"2013","journal-title":"Allergy"},{"key":"2019111709230767900_B16","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00508-012-0293-z","article-title":"European Competence Network on Mastocytosis (ECNM): 10 year jubilee, update, and future perspectives","volume":"124","author":"Valent","year":"2012","journal-title":"Wien Klin Wochenschr"},{"key":"2019111709230767900_B17","article-title":"Large maculopapular cutaneous lesions are associated with a favorable outcome in childhood-onset mastocytosis","author":"Wiechers","journal-title":"J Allergy Clin Immunol"},{"key":"2019111709230767900_B18","article-title":"Cutaneous manifestations in mastocytosis: consensus report of the European Competence Network on Mastocytosis (ECNM), AAAAI and EAACI","author":"Hartmann","journal-title":"J Allergy Clin Immunol"},{"key":"2019111709230767900_B19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2559.1979.tb03017.x","article-title":"Mast cells and mast cell neoplasia: a review","volume":"3","author":"Lennert","year":"1979","journal-title":"Histopathology"},{"key":"2019111709230767900_B20","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1111\/1523-1747.ep12468882","article-title":"Classification and diagnosis of mastocytosis: current status","volume":"96","author":"Metcalfe","year":"1991","journal-title":"J Invest Dermatol"},{"key":"2019111709230767900_B21","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"Response criteria for advanced systemic mastocytosis: an International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Competence Network on Mastocytosis (ECNM) consensus proposal","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"key":"2019111709230767900_B22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000048187","article-title":"Cutaneous mastocytosis\u2014clinical heterogeneity","volume":"127","author":"Hartmann","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"2019111709230767900_B23","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/00000478-199809000-00013","article-title":"Diagnostic value of immunostaining for tryptase in patients with mastocytosis","volume":"22","author":"Horny","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"2019111709230767900_B24","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"2019111709230767900_B25","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/all.12436","article-title":"Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis","volume":"69","author":"Valent","year":"2014","journal-title":"Allergy"},{"key":"2019111709230767900_B26","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019111709230767900_B27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2141.2001.02783.x","article-title":"Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis","volume":"113","author":"Fritsche-Polanz","year":"2001","journal-title":"Br J Haematol"},{"key":"2019111709230767900_B28","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"2019111709230767900_B29","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"2019111709230767900_B30","doi-asserted-by":"crossref","first-page":"e43090","DOI":"10.1371\/journal.pone.0043090","article-title":"Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis","volume":"7","author":"Traina","year":"2012","journal-title":"PLoS One"},{"key":"2019111709230767900_B31","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2010.031690","article-title":"Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis","volume":"96","author":"Wilson","year":"2011","journal-title":"Haematologica"},{"key":"2019111709230767900_B32","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"A. Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"2019111709230767900_B33","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia"},{"key":"2019111709230767900_B34","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"key":"2019111709230767900_B35","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ajh.23380","article-title":"Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components","volume":"88","author":"Wang","year":"2013","journal-title":"Am J Hematol"},{"key":"2019111709230767900_B36","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdu047","article-title":"Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal","volume":"25","author":"Valent","year":"2014","journal-title":"Ann Oncol"},{"key":"2019111709230767900_B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.10072","article-title":"Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA)","volume":"58","author":"Escribano","year":"2004","journal-title":"Cytometry B Clin Cytom"},{"key":"2019111709230767900_B38","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/01.pas.0000138181.89743.7b","article-title":"CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens","volume":"28","author":"Sotlar","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"2019111709230767900_B39","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0145-2126(01)00041-8","article-title":"Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis","volume":"25","author":"Sperr","year":"2001","journal-title":"Leuk Res"},{"key":"2019111709230767900_B40","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"2019111709230767900_B41","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.exphem.2010.05.006","article-title":"In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V","volume":"38","author":"B\u00f6hm","year":"2010","journal-title":"Exp Hematol"},{"key":"2019111709230767900_B42","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"2019111709230767900_B43","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","article-title":"Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells","volume":"39","author":"Krauth","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"2019111709230767900_B44","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1182\/blood.V120.21.799.799","article-title":"KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 Trial","volume":"120","author":"Gotlib","year":"2012","journal-title":"Blood"},{"key":"2019111709230767900_B45","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/98\/1251552\/bep00115000098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/98\/1251552\/bep00115000098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:23:25Z","timestamp":1573982605000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/98\/20767\/Diagnosis-and-management-of-mastocytosis-an"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.98","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}